Project Grant HT94252510861
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This federal Project Grant award of $319,542.00, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports research at Brigham & Women's Hospital Inc. to investigate the modulation of epigenetic regulators controlling pathogenic astrocytes for the treatment of multiple sclerosis (MS). The research aims to advance scientific understanding and develop innovative therapeutic approaches for this chronic neurological...
- Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
- The $925,344 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to Brigham & Womens Hospital Inc. will support research to "MODULATE MICROGLIA AND ASTROCYTES TO TREAT ALZHEIMER'S DISEASE AND RELATED DEMENTIAS". The 3-year grant, awarded on April 15, 2024, will fund innovative biomedical research focused on developing new treatments for Alzheimer's disease and other neurodegenerative conditions by investigating the...
- The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
- The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
- Brigham & Women's Hospital Inc. was awarded a $596,016 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research and healthcare services...
- This federal Project Grant award of $864,498.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research by Brigham & Women's Hospital Inc. at the Department of Faulkner Pathology in Boston, MA. The research project aims to investigate neuroinflammation mechanisms to promote neurological recovery after traumatic spinal cord injury. The 3-year award period runs from August 1, 2025 to July 31, 2028. As a subsidiary of the larger...
- This federal Project Grant award, valued at $999,999.00 and awarded by the Defense Health Agency, supports research under the Military Medical Research and Development program (CFDA 12.420) to investigate "EBV Signatures in Relapsing and Progressive Forms of MS" at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System. This medical research grant will advance scientific understanding of the relationship between Epstein-Barr virus (EBV) and the development of...
- The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
- Brigham & Women's Hospital Inc. was awarded an $895,001 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The two-year award will support in vitro studies targeting proinflammatory mediators to restore regulatory T cell homeostatic expansion and function in amyotrophic lateral sclerosis. The research aims to develop surrogates for in vivo applications in investigating medical solutions for the...